FDA warning letters
Weekly Research Update · September 11, 2026
INDUSTRY UPDATE
On September 1 the FDA posted five warning letters issued August 24 to online research-peptide sellers: Peak Performance Peptides, Royal Peptides LLC, NuScience Peptides LLC, Peptide Partners LLC, and TXP Innovations LLC (Tex Peptides). Reviewed products included retatrutide (“GLP-3R”), semaglutide, SS-31/Elamipretide, Tesamorelin, PT-141, and bacteriostatic water — all treated as unapproved new drugs.
The agency explicitly rejected “research use only / not for human consumption” language where marketing, pairing with bacteriostatic water, or claims established intended human use. Intended-use doctrine overrides disclaimers. This is a direct enforcement signal against the research-peptide e-commerce model. Research-use-only positioning remains high-risk when any human-use signals exist.
RESEARCH UPDATE
New U.S. Clinical Trial Posted for BPC-157
ClinicalTrials.gov NCT07803250 was first posted / last updated September 3, 2026. University of Arkansas Phase 1 randomized, double-blind, placebo-controlled pilot (estimated n=30, not yet recruiting). Daily subcutaneous BPC-157 vs saline for 90 days after arthroscopic rotator cuff repair; endpoints include strength, MRI healing, PROMs, and biomarkers. Estimated start January 2027. This is a rare formal U.S. academic registration for BPC-157. It remains investigational and does not change compounding or commercial status.
NCT07803250 · Phase 1 · Est. n=30 · Not yet recruiting
90-day SC protocol · Est. start January 2027
RECENT RESEARCH & SCIENCE LINKS
FDA Warning Letter — Peak Performance Peptides (issued Aug 24, posted Sept 1, 2026)
ClinicalTrials.gov NCT07803250 — BPC-157 after rotator cuff repair (posted Sept 3, 2026)
https://clinicaltrials.gov/study/NCT07803250
FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (live as of Sept 7, 2026)
All products are intended strictly for research use only — not for human consumption, diagnostic, or therapeutic purposes.